Only 1 million reads for liquid biopsy
Limit of detection down to 0.1% VAF
>95% VAF quantitation accuracy
Compatible with several sample types
VarMap NGS Panels preferentially amplify variant molecules, resulting in a reduction of required sequencing reads by 60-fold compared to deep sequencing approaches.
Detects over 6300 COSMIC mutations in over 60 genes
Limit of detection down to 0.1% VAF
>95% VAF quantitation accuracy
6-hour DNA-to-Library workflow
Compatible with several sample types
CNV+ panels use QASeq technology, which is more sensitive than ddPCR. The panels detect deletions and mutations, that can not be done with IHC. QASeq technology allows analyzing thousands of loci, while ddPCR analyzes 1 locus.
Detects 84 mutation hotspots in 14 genes and detect ERBB2 Copy Number Variations (CNVs) in a single reaction
Limit of detection down to 0.1% VAF
Detects up to 500 COSMIC mutations
Accurate quantitation
Compatible with several sample types
NuProbe’s BDA technology enriches the variant allele frequency (VAF) of mutations by over 200-fold, improving Sanger’s limit of detection of 20% VAF to 0.1% VAF.
Detects 254 AML hotspot mutations in FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 genes
Detects 400 mutations in exons 18, 19, 20, and 21 in FFPE and plasma samples
Detects mutations in codons 596–601 in FFPE and plasma samples
Automatically design custom BDA assays
2-3 days
Limit of detection down to 0.1% VAF
NGSure’s proprietary algorithm designs custom BDA assays with a limit of detection of 0.1% VAF, significantly expanding the range of mutations detected by NGS.
HOUSTON, Feb. 22, 2021 /PRNewswire/ — NuProbe, a genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, launches its VarMapTM Pan-Cancer NGS Panel. The VarMapTM Pan-Cancer NGS Panel uses the quantitative blocker displacement amplification…
HOUSTON and SHANGHAI, Jan. 11, 2021 /PRNewswire/ — NuProbe, a genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, announces the closing of its oversubscribed $42M fundraising. The lead investors for this financing round are BioTrack…
HOUSTON, Nov. 16, 2020 /PRNewswire/ — NuProbe, an innovator of genomics and molecular diagnostics technologies, announces the launch of the Augury™ platform for automated design of customized liquid biopsy NGS panels. …
HOUSTON, June 22, 2020 /PRNewswire/ — NuProbe and Weigao Group announced a strategic collaboration, wherein the two parties will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a…
HOUSTON, April 22, 2020 /PRNewswire/ — NuProbe, a molecular diagnostic startup, announced the addition of two world-renowned oncologists to their clinical advisory board: Amir A. Jazaeri, M.D., from the University…
© 2021 NuProbe. All Rights Reserved. This website uses cookies. By continuing to use this site, you accept our use of cookies. View our Privacy Policy
